Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 50/100

Full Year 2019 Affimed NV Earnings Call Transcript

Apr 28, 2020 / 12:30PM GMT
Release Date Price: $30.26
Operator

Good day, and welcome to Affimed's Fourth Quarter and Full Year 2019 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, today's conference is being recorded.

I'll now introduce your host for today's conference, Greg Gin, Head of Investor Relations at Affimed. Please go ahead.

Gregory Gin
Affimed N.V. - Head of IR

Thank you, Raffy. I'd like to welcome and thank everyone for joining us for Affimed's conference call to discuss the company's full year 2019 financial results and operational progress. This morning, Affimed issued a press release, which is posted on our website at www.affimed.com.

On the call today with prepared remarks are Adi Hoess, Chief Executive Officer of Affimed; Andreas Harstrick, Chief Medical Officer; and Michael Wolf, Head of Finance. We are also joined by Arndt Schottelius, Chief Scientific Officer; Wolfgang Fischer, Chief Operating Officer; and Denise Mueller, Chief Business Officer, who will be available for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot